High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions
- PMID: 23887712
- PMCID: PMC3731665
- DOI: 10.1038/ncomms3218
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions
Erratum in
- Nat Commun. 2013;4:2577. Zucman Rossi, Jessica [corrected to Zucman-Rossi, Jessica]
Abstract
Somatic mutations activating telomerase reverse-trancriptase promoter were recently identified in several tumour types. Here we identify frequent similar mutations in human hepatocellular carcinomas (59%), cirrhotic preneoplastic macronodules (25%) and hepatocellular adenomas with malignant transformation in hepatocellular carcinomas (44%). In hepatocellular tumours, telomerase reverse-transcripase- and CTNNB1-activating mutations are significantly associated. Moreover, preliminary data suggest that telomerase reverse-trancriptase promoter mutations can increase the expression of telomerase transcript. In conclusion, telomerase reverse-trancriptase promoter mutation is the earliest recurrent genetic event identified in cirrhotic preneoplastic lesions so far and is also the most frequent genetic alteration in hepatocellular carcinomas, arising from both the cirrhotic or non-cirrhotic liver.
Figures
Comment in
-
TERT promoter mutations: gatekeeper and driver of hepatocellular carcinoma.J Hepatol. 2014 Sep;61(3):685-7. doi: 10.1016/j.jhep.2014.05.028. Epub 2014 May 22. J Hepatol. 2014. PMID: 24859456 No abstract available.
Similar articles
-
The role of telomeres and telomerase in cirrhosis and liver cancer.Nat Rev Gastroenterol Hepatol. 2019 Sep;16(9):544-558. doi: 10.1038/s41575-019-0165-3. Epub 2019 Jun 28. Nat Rev Gastroenterol Hepatol. 2019. PMID: 31253940 Review.
-
Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis.Mod Pathol. 2016 Jan;29(1):43-50. doi: 10.1038/modpathol.2015.119. Epub 2015 Oct 30. Mod Pathol. 2016. PMID: 26516697
-
TERT promoter mutations in primary liver tumors.Clin Res Hepatol Gastroenterol. 2016 Feb;40(1):9-14. doi: 10.1016/j.clinre.2015.07.006. Epub 2015 Aug 31. Clin Res Hepatol Gastroenterol. 2016. PMID: 26336998 Review.
-
Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.Hepatology. 2014 Dec;60(6):1983-92. doi: 10.1002/hep.27372. Epub 2014 Oct 27. Hepatology. 2014. PMID: 25123086
-
TERT promoter mutations: gatekeeper and driver of hepatocellular carcinoma.J Hepatol. 2014 Sep;61(3):685-7. doi: 10.1016/j.jhep.2014.05.028. Epub 2014 May 22. J Hepatol. 2014. PMID: 24859456 No abstract available.
Cited by
-
Genomic profiling informs therapies and prognosis for patients with hepatocellular carcinoma in clinical practice.BMC Cancer. 2024 Jun 3;24(1):673. doi: 10.1186/s12885-024-12407-2. BMC Cancer. 2024. PMID: 38825709 Free PMC article.
-
Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma.Clin Transl Med. 2024 May;14(5):e1703. doi: 10.1002/ctm2.1703. Clin Transl Med. 2024. PMID: 38769666 Free PMC article.
-
Hepatocellular carcinoma: Advances in systemic therapies.F1000Res. 2024 May 7;13:104. doi: 10.12688/f1000research.145493.2. eCollection 2024. F1000Res. 2024. PMID: 38766497 Free PMC article. Review.
-
Hepatocellular Carcinoma: Current Drug Therapeutic Status, Advances and Challenges.Cancers (Basel). 2024 Apr 20;16(8):1582. doi: 10.3390/cancers16081582. Cancers (Basel). 2024. PMID: 38672664 Free PMC article. Review.
-
Genetic Analyses of Primary Liver Cancer Cell Lines: Correspondence With Morphological Features of Original Tumors.Cancer Genomics Proteomics. 2024 May-Jun;21(3):260-271. doi: 10.21873/cgp.20445. Cancer Genomics Proteomics. 2024. PMID: 38670592 Free PMC article.
References
-
- Forner A., Llovet J. M. & Bruix J. Hepatocellular carcinoma. Lancet 379, 1245–1255 (2012). - PubMed
-
- Nault J. C. & Zucman-Rossi J. Genetics of hepatobiliary carcinogenesis. Semin. Liver. Dis. 31, 173–187 (2011). - PubMed
-
- Fujimoto A. et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat. Genet. 44, 760–764 (2012). - PubMed
-
- Farazi P. A. & DePinho R. A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6, 674–687 (2006). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous